Related Articles for PubMed (Select 16504023)

Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India.

Smita J, Soma D, Beverly B, Albert P, JoAnn K, Fang G, Missy C, Lydia ST, Anjali P, Arun R, Sanjay M, Steven J R; HIV Prevention Trial Network (HPTN) 047 Protocol Team.

AIDS Res Ther. 2006 Feb 20;3:4.

PMID: 16504023 [PubMed]

Related Articles Free article in PMC

Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.

El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, Soto-Torres L, Kwiecien A.

AIDS. 2006 May 12;20(8):1109-16.

PMID: 16691061 [PubMed - indexed for MEDLINE]

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Mâsse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team.

AIDS. 2006 Feb 28;20(4):543-51.

PMID: 16470118 [PubMed - indexed for MEDLINE]

Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z; HIV Prevention Trials Network (HPTN) 020 Protocol Team.

AIDS. 2003 Feb 14;17(3):321-9.

PMID: 12556685 [PubMed - indexed for MEDLINE]

Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.

Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter III AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, Van Damme L, Celum CL.

J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):476-83. Erratum in: J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):118.

PMID: 12869836 [PubMed - indexed for MEDLINE]

Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India.

Joshi S, Joglekar N, Ghate M, Unni J, Risbud A, Bentley M, Shepherd M, Bollinger R, Mehendale S.

Indian J Med Res. 2003 Apr;117:152-7.

PMID: 14604303 [PubMed - indexed for MEDLINE]

A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.

Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, Laga M, Kitchen V.

Sex Transm Infect. 2000 Apr;76(2):126-30.

PMID: 10858715 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report.

Joshi SN, Dutta S, Kumar BK, Katti U, Kulkarni S, Risbud A, Mehendale S.

Sex Transm Infect. 2008 Oct;84(5):343-7. Epub 2008 Apr 21.

PMID: 18426844 [PubMed - indexed for MEDLINE]

Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.

Joglekar N, Joshi S, Kakde M, Fang G, Cianciola M, Reynolds S, Mehendale S; HIV Prevention Trial Network 047 Protocol Team.

AIDS Care. 2007 Jul;19(6):817-21.

PMID: 17573603 [PubMed - indexed for MEDLINE]

10:

Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India--Phase I study.

Joglekar NS, Joshi SN, Navlakha SN, Katti UR, Mehendale SM.

Indian J Med Res. 2006 Apr;123(4):547-52.

PMID: 16783046 [PubMed - indexed for MEDLINE]

11:

Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India.

Joshi SN, Katti U, Godbole S, Bharucha K, B KK, Kulkarni S, Risbud A, Mehendale S.

Trans R Soc Trop Med Hyg. 2005 Oct;99(10):769-74.

PMID: 16084547 [PubMed - indexed for MEDLINE]

12:

Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.

Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L.

AIDS. 2005 Dec 2;19(18):2157-63.

PMID: 16284466 [PubMed - indexed for MEDLINE]

13:

Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners.

Trottier S, Omar RF, Désormeaux A, Drouin J, Gagnon MT, Vezina F, Guilbert E, Mâsse B, Bergeron MG.

Contraception. 2007 Aug;76(2):117-25. Epub 2007 Jun 22.

PMID: 17656181 [PubMed - indexed for MEDLINE]

14:

Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.

Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z.

Clin Infect Dis. 2001 Feb 1;32(3):476-82. Epub 2001 Jan 26.

PMID: 11170957 [PubMed - indexed for MEDLINE]

15:

Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.

van de Wijgert JH, Braunstein SL, Morar NS, Jones HE, Madurai L, Strickfaden TT, Moodley M, Aboobaker J, Ndlovu G, Ferguson TM, Friedland BA, Hart CE, Ramjee G.

J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):538-46.

PMID: 18193495 [PubMed - indexed for MEDLINE]

16:

A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.

Bakobaki JM, Lacey CJ, Bukenya MI, Nunn AJ, McCormack S, Byaruhanga RN, Okong P, Namukwaya SW, Grosskurth H, Whitworth JA.

AIDS. 2005 Dec 2;19(18):2149-56.

PMID: 16284465 [PubMed - indexed for MEDLINE]

17:

Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria.

Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, Taylor D, McNeil L, Mehta N, Umo-Otong J, Otusanya S, Crucitti T, Abdellati S.

PLoS ONE. 2008;3(11):e3784. Epub 2008 Nov 21.

PMID: 19023429 [PubMed - in process]